Intra-articular and peri-articular glucocorticoid (GC) injections are common in sports medicine. However, from 1st January 2022, all injectable GC routes (including intra-articular administration (IA)) will be prohibited in-competition by World Anti-Doping Agency (WADA). Due to these rules, an IA GC treatment out-of-competition could result in an adverse analytical finding (AAF) in-competition if the washout period is not clearly defined. The aim of this study is to determine the urinary excretion profile of triamcinolone acetonide following IA to help in the definition of the washout periods.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
20
knee intra-articular intra-articular ultrasound-guided infiltration of Triamcinolone acetonide
Centre Hospitalier Régional Universitaire de Nancy.
Vandœuvre-lès-Nancy, France
RECRUITINGDetermination of the excretion profile of triamcinolone acetonide in urine following intra-articular ultrasound-guided injection
For subjects with a glucocorticoids urinary value below the 15 ng/ml threshold at D0 (before injection), identification of the date (up to 35 days) following the intra-articular ultrasound-guided injection which will correspond in the standards of the World Agency (under 15 ng/ml)
Time frame: Change from baseline, pre-injection (day 0) to date (up to 35 days) where glucocorticoids urinary value below the 15 ng/ml
Modeling of the excretion profile of triamcinolone acetonide in urine following intra-articular ultrasound-guided injection.
Evolution of urinary triamcinolone acetonide concentration
Time frame: evolution glucocorticoids urinary value from baseline, pre-injection (day 0) to Day 35
Determination of the excretion profile of cortisol in urine following intra-articular ultrasound-guided injection to evaluate systemic effect
Time frame: Change from baseline, pre-injection (day 0) glucocorticoids urinary value up to 35 days
Determination of the excretion profile of triamcinolone acetonide in DBS anti-doping test following intra-articular ultrasound-guided injection.
Time frame: Change from baseline, pre-injection (day 0) glucocorticoids DBS value up to 35 days
Modeling of the excretion profile of triamcinolone acetonide in DBS anti-doping test following intra-articular ultrasound-guided injection.
Evolution of blood triamcinolone acetonide concentration
Time frame: evolution glucocorticoids blood value from baseline, pre-injection (day 0) to Day 35
Determination of cortisol levels in DBS to evaluate systemic effect
Time frame: Change from baseline, pre-injection (day 0) glucocorticoids DBS value up to 35 days
Identification of GCs on hair mark presence one month after intra-articular ultrasound-guided injection of triamcinolone acetonide.
Time frame: Change from baseline, pre-injection (day 0) glucocorticoids hair value up to 35 days
Evaluation of the impact of exogenous corticosteroids on endogenous steroids profile (androgens and GCs) in DBS samples.
Mesure of blood exogenous corticosteroids on endogenous steroidsconcentration
Time frame: Change from baseline, pre-injection (day 0) glucocorticoids DBS value up to 35 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.